Skip to main content
Figure 4 | Experimental Hematology & Oncology

Figure 4

From: Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies

Figure 4

Flow cytometric analysis of WSU-WM xenograft tumors. A. Phenotype of tumor cells in control (untreated) and following rituximab therapy, B. CD20 expression in residual tumors removed at days 7 and 9 post completion of RTX therapy compared with day of completion of therapy (day 0) and with tumors of untreated animals (untreated).

Back to article page